SCHEMBL143238

SCHEMBL143238

COC(=O)c1ccc2c(c1)[nH]c1c(C(=O)O)cc(-c3ccc(OC)c(F)c3)nc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 0.57
DHODH Q02127 1/20 0.43
DYRK1A Q13627 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
JAK3 P52333 1/20 0.42
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
EPRS1 P07814 1/20 0.41
PARP1 P09874 1/20 0.41
PDE10A Q9Y233 1/20 0.41
PDGFRB P09619 1/20 0.40
KIF11 P52732 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146426 0.94 JAK2 (0.59) JAK2DHODHDYRK1AJAK1TYK2
SCHEMBL140503 0.92 JAK2 (0.68) JAK2JAK1TYK2JAK3
SCHEMBL144496 0.87 JAK2 (0.70) JAK2JAK1TYK2JAK3LMNA
SCHEMBL142452 0.84 JAK2 (0.58) JAK2DHODHKDM4EGAAHPGD
SCHEMBL141180 0.78 JAK2 (0.46) JAK2EPRS1
SCHEMBL146396 0.76 JAK2 (0.82) JAK2JAK1TYK2JAK3
SCHEMBL140595 0.76 JAK2 (0.46) JAK2DYRK1A
SCHEMBL141898 0.76 JAK2 (0.80) JAK2
SCHEMBL142655 0.75 JAK2 (0.78) JAK2DYRK1ALMNARAB9AEPRS1
SCHEMBL142717 0.75 JAK2 (0.46) JAK2DHODHLMNARAB9APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885DHODH 3348/4885DYRK1A 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.